Rationale Previous studies indicate that psychosocial stressors could accelerate amyloid-β (Aβ) levels and accelerate plaque deposition in mouse models of Alzheimer disease (AD). Stressors enhanced the release of corticotrophinreleasing factor (CRF), and exogenous CRF administration mimicked the effects of stress on Aβ levels in mouse models of AD. However, whether CRF receptor 1 (CRF1) antagonists could influence the stress-induced acceleration of an AD-like process in mouse models has not been well studied. Objective We sought to examine whether CRF1 antagonists inhibit the effects of isolation stress on tissue Aβ levels, Aβ plaque deposition, and behaviors related to anxiety and memory in Tg2576 mice, and to investigate the molecular mechanism underlying such effects.
Introduction
Alzheimer disease (AD) is the most common type of dementia in the elderly and currently affects approximately 5 million Americans (www.alz.org Facts and Figures) . The pathological changes of AD include the formation of extracellular amyloid-β (Aβ) plaques and intracellular phosphorylated tau tangles in the brain (Harrington 2012) . Although the exact causes of these neuropathological changes are unknown, both genetic and environmental factors are thought to be involved (Miller and O'Callaghan 2008; Migliore and Coppede 2009) . Current pharmacotherapies, such as acetylcholinesterase inhibitors and an N-methyl-D-aspartate antagonist, memantine, can ameliorate some of the behavioral symptoms. However, none of the approved treatments for AD have been shown to slow or halt the progression of this disease (Herrmann et al. 2011; Tayeb et al. 2012) . Thus, new strategies to block or delay the pathogenesis and prevent cognitive decline in AD are greatly needed.
Stress is common in daily life and may be especially high in AD patients who are less resilient because of age, other health problems, and limited resources. The results of recent studies suggest that stress can significantly affect the onset and progression of AD. For example, individuals prone to psychological distress are twice as likely to develop AD (Wilson et al. 2005 (Wilson et al. , 2006 . Elevated plasma cortisol levels, often an indicator of stress, have been reported in patients with AD (Swanwick et al. 1998; Umegaki et al. 2000; Rehman 2002) , and higher plasma cortisol levels were correlated with severity of cognitive decline in AD patients (Csernansky et al. 2006) . Considering other elements of the HPA axis, investigators have reported a reduction in corticotrophin-releasing factor (CRF) immunoreactive cells and increases in the density of postsynaptic CRF receptors in the brain of AD patients (Whitehouse et al. 1987; Pomara et al. 1989; Behan et al. 1995; . These changes in the hypothalamicpituitary-adrenal (HPA) axis in AD patients are unlikely to be secondary to depression, as AD patients without depression also have higher cerebrospinal fluid cortisol levels as compared with controls (Hoogendijk et al. 2006 ). However, hippocampal degeneration could lead to increases in cortisol in AD patients via reductions in negative feedback within the HPA axis (O'Brien et al. 1996) .
Genetically manipulated mice that imitate some of the neuropathological changes of AD provide an opportunity to investigate the impact of stress on AD pathogenesis and cognitive function, and reveal the molecular mechanisms underlying these effects. Studies from our group and others indicate that behavioral stressors can accelerate the production of Aβ and its incorporation into Aβ plaques, and increase hippocampal tau phosphorylation in transgenic mouse models (Dong et al. 2004 (Dong et al. , 2008 Rissman et al. 2007; Carroll et al. 2011; Cuadrado-Tejedor et al. 2012) . CRF and CRF receptor 1 (CRF1) play critical roles in regulation of stress-induced neuropathogenesis and behavioral deficits in mouse models of AD (Kang et al. 2007; Dong et al. 2008; Carroll et al. 2011; Rissman et al. 2012) . In this study, we examined the effectiveness of CRF1 antagonists on tissue Aβ levels, amyloid plaque deposition, and behaviors related to anxiety and memory in Tg2576 mice under stressed conditions. Also, we investigated possible molecular pathways by which such effects might be mediated using hippocampal neurons from Tg2576 mice in culture.
Materials and methods

Transgenic mouse model
Tg2576 mice of both genders [B6;SJL-Tg(APPSWE)2576Kha; Taconic Farms Inc. Germantown, NY] were used for this study. All animal procedures were performed in accordance with the National Institutes of Health (NIH) Guidelines and Animal Studies Committee at Northwestern University. Tg2576 mice have the K670N-M671L mutation, driven by a hamster prion protein promoter, and over-expressed human APP 695. Heterozygous Tg2576 (+/−) males were bred with C57B6/SJL females (The Jackson Laboratory, Bar Harbor, ME). Screening for transgenic mice in offspring was performed by genotyping DNA obtained from tail biopsies. Generally, the ratio for Tg2576 mice (Tg+/-) in each litter was 25-40 % (i.e., 1-4 Tg2576 mice from each litter depending on the litter size). Tg2576 mice showed Aβ plaques at 9 to 10 months of age, and the cognitive deficits occurred earlier (Hsiao et al. 1996) .
Animal groups and CRF1 antagonist administration in vivo A total of 60 Tg2576 mice were used for the 1-week stress and CRF1 antagonist-treated study (three to five mice per group with males and females evenly distributed in each group). Tg2576 pups from each litter were randomly divided to isolation stressed and standard group-housed (see below) with and without drug administration immediately after weaning (21 days of age) to avoid the litter effects. Only one Tg2576-positive pup from each litter could be assigned to a treatment group in which every individual animal came from a different litter (three to five litters for 1 week treatment, five to seven litters for 6 months treatment). CRF1 antagonists antalarmin and R121919 are nonpeptide compounds that can pass through the blood-brain barrier (Sabino et al. 2006; Funk et al. 2007 ). Drug-administered groups were given either antalarmin (suspended in warm water with 20 % Tween-80) or R121919 (suspended in warm water) at one of three doses (5, 10, and 20 mg/kg) by intraperitoneal (IP) injection once a day for 7 days. Control groups were IP-injected the vehicles that were used for dissolving drugs. For the chronic stress and CRF1 antagonist study, a total of 24 Tg2576 pups (five to seven mice per group) were randomly divided to isolation stressed and standard group housing until 4 months old and then were administered antalarmin for 6 months. Antalarmin (20 mg/kg) was suspended in drinking water for drug administration (first suspended in warm water with 20 % Tween-80, then diluted in drinking water), and the final concentration of Tween-80 in the drinking water is 0.2 %. The same vehicle was used for the control. To ensure the consistency of drug dosing and that the presence of antalarmin did not influence daily water consumption, we measured the amount of water consumed by each mouse weekly and calculated the total and mean volume of drinking water with and without the drug. The mean amount of consumption between groups was not significantly different [F 1,21 =0.34; P=0.56] . We also measured body weight each week to ensure that antalarmin administration did not affect mouse food chow consumption. The mean body weight between groups was not significantly different [F 1,21 ) and placed in a separate area (our satellite facility) from other animals to prevent visual contact from weaning for 7 days (from 21 days to 28 days of age) and 9 months (from 21 days to 4 months of age) before drug treatment then continued isolation stress for 6 months during drug treatment until 10 months of age. Control animals (group-housed) were housed at three animals per standard cage for the same period. Food and water were available ad libitum (Dong et al. 2004 (Dong et al. , 2008 .
Behavioral tests
Animals were habituated in the testing room (next to satellite facility) for at least 30 min before each test. All behavioral tests were performed starting at 9:00AM. The testing rooms and housing facility were light controlled to automatically turn on at 6:00AM and off at 6:00PM.
Elevated plus maze (Handley and Mithani 1984) . The elevated plus-maze is an apparatus composed of two open arms (10×50 cm) and two perpendicular closed arms [10×50× 40 cm (wall height)] surrounding a 10×10-cm center platform 50 cm above the ground. A camera was assembled above the maze for recording. The mouse was placed on the center platform facing one of the closed arms and allowed to freely explore the plus maze for 5 min. The following measures were quantified by two trained observers blind to the group assignment of the animals: number of entries into the open arms, total number of entries, time spent in the open arms, time spent on the center platform.
Spontaneous alternation (Mitani et al. 2012; Hsiao et al. 1996) . The spontaneous alternation apparatus consists of a three-arm (5 cm wide×21 cm long×15.5 cm high) Y-shaped maze. Mice were placed in the central region facing one of the closed arms and were allowed to freely explore the arms for 5 min without investigator presence while a camera recorded its movements. A successful alternation was defined as discrete and successive entries into each open arm, including events where the animal directly progresses from one arm to the next in consecutive fashion (that is ABC, ACB, BAC, BCA, CAB, and CBA) without reentering the two previously visited arms. The locomotion index were calculated as the overall number of arm entries, whereas the working memory index (percent correct alternation) were calculated by dividing the number of total successful alternations divided by the total number of possible alternations (i.e., the number of total entries minus two) multiplied by 100 %.
Plasma antalarmin measurement
To confirm chronic administration of antalarmin through drinking water would be sufficient and compatible compared with administration of IP injection, we measured the antalarmin concentration in the plasma when the blood was collected by rapid retro-orbital phlebotomy (less than 1 min) after 1 week of antalarmin treatment (two time points: 6AM, 30 min after antalarmin IP injection, and 6PM at same day), and 6PM at the end of the 6 months of antalarmin treatment (antalarmin in drinking water). Antalarmin was extracted from 25.0 μL mouse plasma by liquid-liquid extraction with methyl tert-butyl ether. Briefly, internal standard solution (25.0 μL of 10.0 ng/mL R121919 for antalarmin analysis) was added to thawed plasma samples in a 96-well plate. Following addition of water and mixing, the samples were processed by supported liquid extraction. The eluates resulting from extraction were evaporated to dryness under a stream of nitrogen (nominal 40°C, 20 psi). The residues were reconstituted in the mobile phase and submitted for analysis by liquid chromatographytandem mass spectrometry (MS/MS). Separation was achieved on a Thermo Electron Betasil Silica-100 column (50×3 mm, 5 μm) at a flow rate of 0.4 mL/min with an isocratic mobile phase composed of acetonitrile/water/glacial acetic acid/trifluoroacetic acid (87.5:12.5:0.5:0.05, v/v/v/v). Precursor/fragment ions: 379.3→307.2m/z (Antalarmin) were monitored by MS/MS using electrospray ionization in the positive ion mode on a Sciex API5000. Concentrations of antalarmin were calculated using peak area ratios (analyte/ internal standard). The calibration curves were generated using a linear regression with a weighting of 1/x 2 . The results showed plasma antalarmin concentrations 580±117.22 ng/ml (30 min after injection), 40.33±4.50 ng/ml (12 h after injection), and 34.267±8.63 (6 months in drinking water), which indicated that the plasma antalarmin concentrations administrated by drinking water are comparable to the concentrations at 12 h after IP injection.
Plasma corticosterone measurement
The blood was collected by rapid retro-orbital phlebotomy at 6:00 PM before antalarmin treatment, after 1 week of antalarmin treatment and at the end of 6 months of antalarmin treatment. Plasma corticosterone levels were measured using EIA kit (Cayman Chemical Company, Ann Arbor, MI) according to the introduction manual and published methods (Zamora et al. 2009 ). The serum corticosterone content was calculated in picograms per milliliter according to the manufacturer's recommendations.
Brain tissue Aβ measurement
All animals were deeply anesthetized by 50 mg/kg pentobarbital and were quickly perfused by saline to rinse out the blood. For the 1 week drug-treated groups, the cortex and hippocampus in both hemispheres of each animal were dissected on ice and snap-frozen on dry ice then stored in an −80°C freezer. For the 6 month drug-treated groups, one hemisphere of each brain was fixed in 4 % paraformaldehyde for the histological procedure. The cortex and hippocampus of the other hemisphere were dissected on ice and snap-frozen on dry ice, then stored in a −80°C freezer for biochemical analysis.
Levels of Aβ 1-40 and Aβ 1-42 were measured using enzymelinked immunosorbent assay (ELISA) kits (Biosource Inc., Camarillo, CA) according to the manufacturer's instructions and protocols from our previous study (Dong et al. 2004 (Dong et al. , 2008 Kang et al. 2007 . Briefly, the cortex or hippocampus from one hemisphere was homogenized in PBS and centrifuged at 10,000×g for 5 min. The supernatant was collected, and protein quantification was performed using the BCA assay (Bio-Rad Laboratories, Hercules, CA). Samples were analyzed for soluble Aβ using a sandwich ELISA specific for human Aβ 1-40 or Aβ 1-42 (BioSource International Inc., Camarillo, CA) according to the manufacturer's instructions. Duplicate standards (Aβ 1-40 or Aβ 1-42 , from 1,000, 500, 250, 125, 62.5, 31.25, 15.65 , and 0 pg/mL) and tissue samples (120 μg per sample) containing protease inhibitor cocktail tablets (Roche Molecular Biochemicals, Mannheim, Germany) were incubated overnight in antibody-coated plates at 4°C. After washing, the plates were incubated in rabbit anti-human Aβ 1-40 or Aβ 1-42 for 2 h at room temperature and then with horseradish peroxidase-conjugated anti-rabbit IgG for another 2 h. Stabilized chromogen (100 μL) was added to each well and incubated for 30 min in the dark. The absorbance in each well was read with a microplate reader (SPECTRAmax Plus, Molecular Devices Corporation, Sunnyvale, CA). The intra-assay coefficient of variation was 2.9 %.
Aβ plaque immuno-staining and measurement
The hemispheres fixed in 4 % paraformaldehyde for 3 days were transferred into the same fixative with 30 % sucrose for 48 h. The brains were cut into 40-μm-thick serial sections for four sets in the coronal plane using a cryostat (Leica CM 1850 UV; Leica, Nussloch, Germany) (average 35±3 sections/per set). One set of sections were rinsed with PBS, treated with 0.3 % H 2 O 2 in methanol for 30 min to eliminate the endogenous peroxidase activity, and the sections were incubated in a blocking solution of 5 % normal goat serum 0.3 tritonX-100 in PBS for 1 h. Sections were then incubated overnight in the primary antibody for Aβ 1-40 (rabbit polyclonal pan antibody raised against Aβ synthetic peptide, 1:1,000, Biosource, Camarillo, CA) at 4°C. After washing, the sections were incubated in biotinylated anti-rabbit secondary antibody for 2 h, then in an avidin-biotin complex for 1 h at room temperature. Aβ-like immunoreactivity was visualized using a DAB kit (Vector Laboratories, Burlingame, CA).
Aβ plaques were counted in every section of one set (35±3 sections) using a non-biased stereological system program (Olympus, Albertslund, Denmark). Each Aβ plaque was counted as one plaque regardless of its size but was not connected to other Aβ plaques. The total number summed from one set of sections was multiplied by 4 to obtain an estimate of the total number of Aβ plaques in the brain. Aβ plaque sizes were measured using CAST-GRID by drawing an outline of the Aβ plaque areas for Aβ burden (i.e., total Aβ plaque area/brain area in coronal section).
Primary neuronal culture and related assays
The hippocampi from day 0 (P0) Tg2576-positive newborn pups were dissected and digested with 0.25 % trypsin EDTA solution. Neurons were plated into 24-well tissue culture plates coated with 0.1 mg/mL of poly-D-lysine (SigmaAldrich, St. Louis, MO) in high density (4.5×10 5 /cm 2 ). Cells were maintained in neurobasal medium supplemented with B-27, 2 mM glutamine, 100 μg/mL of streptomycin, and penicillin (Invitrogen, Carlsbad, CA) in the incubator at 37°C in a humidified atmosphere of 95 % air and 5 % CO 2 . Cultured neurons were treated at day 14 with different doses of CRF (0.1, 1, and 10 nM), antalarmin (100 nM), and PKA inhibitor H-89 (1 μM). This experiment was repeated three times with three different litters.
MTT cell toxicity assays To test whether the doses of CRF, antalarmin, and H-89 we selected in this study exhibited any neurotoxic effects in the cultured neurons, cells with CRF, antalarmin, and H-89 treatment were added with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole (MTT) 0.5 mg/mL, 4 h before the end of the treatment. MTT is reduced to purple formazan in living cells. A solubilization solution (dimethyl sulfoxide) was added to dissolve the insoluble purple formazan product into a colored solution. The absorbance of this color was measured at a wavelength of 570 nm using a microplate reader. MTT assay showed that exposure to any of the treatments for 48 h did not cause dramatic decreases in the viability of neurons compared with vehicle-treated controls.
Aβ 1-42 levels The cultured neurons were collected at different conditions for measurement of Aβ 1-42 levels using an ELISA kit (see the detailed method above).
PKAIIβ The type IIβ isoform of cAMP-dependent protein kinase (PKAIIβ) is a major mediator of the actions of cAMP in the central nervous system; therefore, we selected PKAIIβ as an indicator to investigate the involvement of cAMP/PKAsignaling in the CRF/CRF1 activity. The primary cultured neurons at 16 days after 48 h of CRF, antalarmin, and H-89 administration were collected and homogenized in 5 volumes of ice-cold homogenization buffer (0.2 % NP-40 and protease inhibitor in PBS buffer). Homogenates were centrifuged at 15,000×g for 20 min at 4°C, and the supernatant was used to measure protein levels (bicinchoninic acid method). A total of 25 mg of each sample was further diluted in sample buffer (Bio-Rad, Hercules, CA), and 15 % polyacrylamide gels were used for sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were transferred to polyvinylidene fluoride membranes probed with rabbit anti-mouse PKAIIβ (1:500) and β-actin (1:1,000) (Santa Cruz Biotechnology, Santa Cruz, CA) followed by horseradish peroxidase-conjugated secondary antibody binding (1:20,000; BD Diagnostic Systems, Sparks, MD). Immunoreactive proteins were visualized using the enhanced chemiluminescence Western blotting detection system (Thermo Fisher Scientific). The light-emitting bands were detected with X-ray film (Thermo Fisher Scientific). Quantification of the blots were performed using Image J software (NIH), by plotting density measurements against the dilution factor in the linear range of signal.
Statistical analysis
Data analysis was carried out by two trained and genotypeblind researchers. Given the small number of Tg2576-positive animals (Tg+) from each litter (one to four Tg+ mice per litter), only one Tg2576 pup from each litter could be assigned to one of four treatment groups. Although no littermates can be included in the same experiment group due to not having exactly four Tg2576 pups in each litter, the assignment of pups to each treatment group was randomized from three to five litters for 1 week treatment and five to seven litters for 6 months treatment. That is, subjects were assigned to treatments in a systematically balanced fashion from each litter. Therefore, in our overall design, except that the corticosterone concentration study is a repeated measure, in all other studies, an individual mouse was approximately represented a variation of treatment. Treatment was not a repeated measurement. However, in order to avoid the potential litter effects confound with treatment effects, we used litter as the unit of analysis and run the model with litter, housing, and drug interactions. No litter effects and interaction effects were found. Thus, based on our design, we performed two-way analysis of variance (ANOVA) for tissue Aβ levels, plaques, and behavioral studies and repeated-measure ANOVA for corticosterone concentration (P<0.05; SPSS). When housing (i.e., isolated vs. group-housed), drug (i.e., antalarmin or R121919 vs. controls), or housing and drug interactions were found, post hoc (Bonferroni/Dunn tests) analysis was used. Finally, the Prism liner regression test was used for calculation of correlation.
Results
Effect of 1 week administration of antalarmin or R121919 on Aβ 1-40 and Aβ 1-42 levels
Using a sub-acute stress paradigm, we determined whether daily administration of CRF1 antagonists (i.e., antalarmin or R121919, at doses of 5, 10, and 20 mg/kg) versus vehicle could prevent the effects of isolation stress on Aβ levels. Twoway ANOVA indicated a significant effect of housing on both Aβ 1-40 (F 1,56 =58.33; P<0.0001) and Aβ 1-42 (F 1,56 =78.71; P<0.0001) levels but a significant effect of drug treatment on only Aβ 1-42 (F 2,56 =5.45; P=0.006) levels. The effect of drug treatment on Aβ 1-4 0 only reached a trend level (F 2,56 = 3.00; P=0.056). Post hoc tests confirmed that isolation housing significantly increased both tissue Aβ 1-40 (Fig. 1a,  P<0 .001) and Aβ 1-42 levels (Fig. 1b, P<0 .001) as compared with the group housing condition. Administration of antalarmin at a dose of 20 mg/kg, but not at doses of 5 or 10 mg/kg, significantly reduced Aβ 1-42 levels as compared with the vehicle (P=0.0146). The effects of R121919 at 20 mg/kg were similar, but only at a trend level (P=0.0755) (Fig. 1b) .
Effect of 6 months administration of antalarmin on tissue Aβ 1-42 levels and amyloid plaque deposition
Because antalarmin administration at 20 mg/kg was associated with reductions of Aβ 1-42 levels in isolated mice under subacute conditions, we used antalarmin at this same dose to test the effects of a CRF1 antagonist on tissue Aβ 1-42 levels and amyloid plaque deposition in mice chronically stressed in isolated housing conditions. Two-way ANOVA indicated a significant effect of housing (F 1,21 =6.17, P=0.024), a significant effect of antalarmin (F 1,21 =15.92, P=0.001), and a trend towards a significant housing × antalarmin interaction (F 1,21 = 3.45, P=0.082) on Aβ 1-42 levels. Post hoc tests indicated that chronic isolation stress significantly increased Aβ 1-42 levels in the cortex and hippocampus, and that these increases were blocked by antalarmin administration (Fig. 2a and b) . Also, there was a significant effect of housing (F 1,21 =21.001, P<0.001), an effect of antalarmin (F 1,21 =17.585, P<0.001), and a housing × antalarmin interaction (F 1,21 =7.475, P= 0.015) on Aβ plaque number in the cortex, and an effect of housing (F 1,21 =14.984, P=0.001), and a trend towards a housing × antalarmin interaction (F 1,21 =4.385, P=0.052) on Aβ plaque number in the hippocampus. Furthermore, there was a significant effect of housing (F 1,21 = 29.913, P<0.0001) and an effect of antalarmin (F 1,21 =12.874, P=0.003) on whole brain amyloid plaque burden. Post hoc tests again indicated that chronic isolation stress significantly increased Aβ plaque deposition in the cortex (P<0.001) and hippocampus (P < 0.05) (Fig. 2c-f) , and that long-term antalarmin administration significantly blocked the effects of isolation on Aβ plaque deposition in both the cortex and hippocampus (Fig. 2c, d, g, and h ).
Effect of 6 months administration of antalarmin on plasma corticosterone levels Two-way repeated-measure ANOVA indicated a significant effect of housing (F 1,24 =143.79, P<0.0001) and a significant housing × antalarmin interaction (F 1,24 =28.109, P=0.0002) on plasma corticosterone levels (e.g., baseline, after 1 week and after 6 months of antalarmin administration). Post hoc tests indicated that isolation housing significantly increased corticosterone levels after chronic isolation stress and that antalarmin administration for 1 week and 6 months (P<.0001) blocked the effects of isolation increased corticosterone levels (Fig. 3) .
Effect of 6 months administration of antalarmin on anxiety-and memory-related behaviors
Using the elevated plus maze test as a measure of anxiety-related behavior, a two-way ANOVA indicated a significant effect of housing (F 1,22 =12.44, P=0.003), a significant effect of antalarmin (F 1,22 =9.83, P=0.006) and a significant housing × antalarmin interaction (F 1,22 = 6.49, P = 0.022) on the amount of time mice spent in the open arm. Similar effects of housing (F 1 , 2 2 = 8.93, P = 0.009) antalarmin (F 1 , 2 2 = 24.21, P < 0.001), and a housing × antalarmin interaction (F 1,22 =5.22, P=0.036) on closed arm entries were also found. Finally, a significant effect of housing (F 1,22 = 9.67, P=0.007) was found on the amount of time spent in the center. Post hoc tests indicated that isolation stress reduced the amount of time mice spent in the open arm (P<0.01), and that these effects were blocked by antalarmin administration (Fig. 4a and b) .
Using a spontaneous alternation test to assess memory-related behavior, a two-way ANOVA indicated a significant effect of antalarmin (F 1 , 22 = 18.76, P<0.001) and a significant housing × antalarmine interaction (F 1,22 =5.12, P=0.043) on the number and percentage (%) of correct alternations. Post hoc tests indicated that isolation stress decreased the number and percentage of correct alternations as compared with group-housing (P < 0.05), and that these effects were blocked by antalarmin administration (Fig. 4c and d) . Effects of CRF and antalarmin on Aβ levels and the cAMP/PKA signaling pathway in cultured hippocampal neurons Because CRF1 is a G-protein-coupled receptor that alters cellular function through the cAMP/PKA signaling pathway in neuronal systems (Jedema and Grace 2004; Hauger et al. 2006 ), we measured Aβ 1-42 and PKAIIβ levels after 48 h of exposure to CRF, antalarmin, and H-89, using ELISA and Western blot analyses in hippocampal neurons cultured from Tg2576 mice. MTT cell toxicity assays indicated there was no effect of CRF administration on neuronal growth at 16 days with CRF for 48 h in cultured hippocampal neurons [ Fig. 5a (vehicle without CRF) vs. Fig. 5b (10 nM CRF for 48 h) ].
Two-way ANOVA indicated a significant effect of CRF on Aβ 1-42 (F 3,16 =15.791, P<.0001) and PKAIIβ levels (F 3,16 = 27.470, P < 0.0001) in cultured hippocampal neurons. Administration of CRF (10 nM) into the cultured medium at 14 days for 48 h resulted in a significant increase in Aβ 1-42 levels (P=0.007) (Fig. 5c) , and administration of 100 nM antalarmin in addition to 10 nM CRF blocked this increase in Aβ 1-42 levels (P = 0.001) (Fig. 5d) . Grouped + Veh) Representative Aβ-immunocytochemical stained sections are shown from the cortex of 10-month-old Tg2576 mice from housed in isolation (Isolated, e, g) or under grouphoused conditions (Grouped, f, h) and treated with antalarmin. Arrowheads indicate the plaques. Scale bar=200 μm shown in panel h also applies to panels e, f, and g Moreover, administration of H-89 in addition to CRF also blocked the effect of CRF on Aβ 1-42 levels (P<0.0001, CRF vs. CRF + H-89, Fig. 5e ). Similarly, antalarmin and H-89 also blocked CRF-induced increases in PKAIIβ levels in cultured hippocampal neurons (P<0.005, CRF vs. CRF + H-89, Fig. 5f  and g ). There was a significant correlation between Aβ 1-42 and PKAIIβ levels in cultures during CRF administration (r 2 =0.72, P<0.0001) (Fig. 5h) .
Discussion
In this study, we evaluated the effect of CRF1 antagonists on tissue Aβ levels and Aβ plaque deposition, as well as behaviors related to anxiety and memory in Tg2576 mice, a commonly used animal model of AD. The effects of CRF1 antagonists were evaluated as a means of reducing the effects of isolation stress under both subacute and chronic conditions. In the subacute study, main effects of both housing and drug administration were observed, but not a significant housing × drug administration interaction, which suggests that CRF1 antagonists may be able to reduce Aβ levels through both stress-related and stress-unrelated mechanisms under subacute conditions. Because antalarmin at a dose of 20 mg/kg displayed the strongest effect in this paradigm, we then used this drug dose to investigate the long-term effects of CRF1 antagonists Aβ plaque deposition and behavior. We then found that 6 months of administration of antalarmin to isolated Fig. 3 Antalarmin decreases plasma corticosterone levels in chronically stressed Tg2576 mice. Isolation housing beginning at weaning until 4 months of age significantly increased the plasma corticosterone levels at 4 months of age (#P<0.001: Isolated + Veh vs. Grouped + Veh). Antalarmin administration significantly decreased the plasma corticosterone levels in isolated mice as compared with isolated vehicle group after 1 week (**P<0.001) and after 6 months(*P<0.05 Isolated + Veh vs. Isolated + Ant). Antalarmin had no significant effects on plasma corticosterone levels in group-housed mice . There was no difference in the total arm entries between isolated and group-housed animals and group-housed mice significantly decreased not only tissue Aβ 1-42 levels, but also amyloid plaque deposition and stressrelated changes in anxiety-and memory-related behaviors. Under these conditions, significant housing × drug administration effects were often observed, suggesting that antalarmin was exerting its effects mainly by blocking the stress-related effects. The observed changes in plasma corticosterone with and without CRF1 antagonist treatment also support the hypothesis that CRF-mediated effects on the HPA axis function may play a critical role involved in the process of amyloid deposition and the pathogenesis of AD. Finally, in our study of hippocampal neurons in culture, we found that CRF could directly stimulate Aβ production without the involvement of the HPA axis, and that CRF1 could reverse the effects of CRF on its signal transduction elements and on Aβ production. These results suggest that CRF and CRF1 may regulate Aβ production both through the HPA axis and as a direct neuromodulator of neuronal activity throughout the cortex and hippocampus (de Souza 1988; Orozco-Cabal et al. 2006; Gallagher et al. 2008) .
Stress has been increasingly recognized as an external factor that can impact the onset and progression of AD (Dong et al. 2004; Wilson et al. 2006; Csernansky et al. 2006; Huang et al. 2010; Alkadhi 2012) . Although the mechanisms involved in the effects of stress on the pathogenesis of AD remain unclear, there is growing evidence that CRF and CRF1 receptors play a critical role in the production and aggregation of both Aβ and tau (Kang et al. 2007; Rissman et al. 2007 Rissman et al. , 2012 Carroll et al. 2011) . Thus, improving our understanding of the precise cellular pathways involved in mediating the effects of CRF and CRF1 receptor on Aβ metabolism will help to identify new drug therapy targets.
CRF exerts its cellular effects by activating one of two known G-protein-coupled receptors: CRF1 and CRF2. Since CRF binds to CRF1 with~40-fold higher affinity, most of its activity in the CNS has been attributed to the activation of CRF1 (Wood and Woods 2007) . CRF1 receptor stimulation primarily activates the cAMP/PKA-signaling cascade in neuronal systems (Jedema and Grace 2004; Hauger et al. 2006) . However, CRF can also couple with the phospholipase C (PLC)/PKC pathway (Ungless et al. 2003; Hauger et al. 2006 ) through CRF receptors. Activation of CRF1 generally stimulates adenylate cyclase activity, thereby increasing levels of cAMP.
Stress can impact prefrontal cortical function by increasing catecholamine release in the prefrontal cortex, which in turn increases cAMP and PKC intracellular signaling. Under certain conditions, this increase can lead to reductions in prefrontal neuronal firing and impairments in working memory (Birnbaum et al. 2004; Hains and Arnsten 2008) . The highest level of CRF-induced adenylate cyclase activation is in the cerebral cortex, an area that is profoundly involved in AD (de Souza 1988; Martin et al. 2005) . Recent studies indicate that PKC plays an important role in the pathophysiology of AD (Choi et al. 2006; Takashima 2006; Nelson et al. 2009) , and increases in PKC activity can stimulate Aβ peptide production and tau protein hyperphosphorylation. In addition, other studies have demonstrated that GPCRs and PKA/PKC signaling pathways play an important role in the pathophysiology of AD (Lee et al. 2004; Choi et al. 2006; Takashima 2006; da Cruz e Silva et al. 2009; Nelson et al. 2009; de Barry et al. 2010; Kim et al. 2011; Thathiah and De Strooper 2011; Thathiah et al. 2013) . For example, some GPCRs directly influence the amyloid cascade through modulation of α-, β-, and γ−secretases, thereby affecting the proteolysis of the APP (Xu et al. 1996; Robert et al. 2001; Thathiah and De Strooper 2011; Thathiah et al. 2013) .
In our study, we found that CRF-induced increases of amyloid Aβ 1-42 levels in cultured hippocampal neurons were highly correlated with increase in PKAIIβ expression. PKAIIβ is a major mediator of the actions of cAMP in the central nervous system of mammals (Li et al. 1996 ) and a key factor of the downstream in the CRF/CRF1 pathway. Further introduction of antalarmin into the medium of cultured neurons for 48 h significantly blocked CRF-induced increases of Aβ 1-42 , as well as increases in PKAIIβ expression. Similarly, treatment with H-89, a PKA inhibitor, blocked CRF-induced increases of Aβ 1-42 and PKAIIβ expression. These results suggest that the cAMP/PKA signaling pathway mediates at least some of the effects of CRF and CRF1 on amyloid production in a mouse model of AD. A limitation of the present study is that only PKAIIβ expression and one PKA inhibitor H-89 was tested. These results need be confirmed by the use of other PKA inhibitors, and the study of other elements of the cAMP/PKA signaling pathway, such as the phosphorylation of cAMP response element binding transcription factors.
Preclinical studies and clinical trials on CRF1 antagonists have been tested in the treatment of depression, anxiety, and irritable bowel disorder. Unfortunately, CRF1 antagonists have had a poor record of success as anti-depressants, perhaps because of problems with bioavailability Koob 2004, 2010; Nielsen 2006; Binneman et al. 2008) . Nevertheless, new CRF1 antagonists are being developed, perhaps with better pharmacodynamics and pharmacokinetic properties and may be available for clinical testing soon (Zorrilla and Koob 2010) . The therapeutic potential of CRF1 antagonists as treatments for neurodegenerative disorders has not yet been evaluated although previous studies on Tg2576 mice shown some evidence CRF1 antagonists block stressinduced Aβ accumulation (Kang et al. 2007; Lee et al. 2009) , and there have been recent reports of the beneficial effects of CRF1 antagonists on tau phosphorylation (Carroll et al. 2011; Rissman et al. 2012 ). The present study is, to our knowledge, the first to evaluate the long-term effects of CRF1 antagonist administration on Aβ production, plaque deposition, and behavior in an animal model of AD. Our results add to the rationale for the further study of CRF1 antagonists in animal models of AD, and in time, clinical trials in AD patients. Since it is not yet possible to interfere with genetic predisposition to AD, the possibility of delaying the onset or progression of neuropathology and concomitant cognitive decline by overcoming a common and substantial environmental factor (i.e., psychosocial stress) may be an attractive strategy.
In summary, our results demonstrate that CRF1 antagonists can decrease Aβ levels and slow Aβ plaque deposition in Tg2576 mice under both stressed and unstressed conditions. CRF1 antagonists also preserve memory-related behaviors in isolation-stressed mice. On the basis of an in vitro experiment, it appears likely that CRF1 and CRF1 antagonists regulate Aβ and behavior through cAMP/PKA signaling pathways. These studies suggest the possibility that these agents, by virtue of their ability to mitigate the effects of stress on the pathogenesis of AD, should be considered as treatments for delaying the onset or progression of AD.
